Home   >  
Ion Channel/Membrane Transporter
Sodium Channel

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Sodium Channel

Chemical Structure Cat. No. Product Name CAS No.
Nicainoprol Chemical Structure
BCP30068 Nicainoprol 76252-06-7
Nicainoprol is a fast-sodium-channel blocking drug, which is a potent antiarrhythmic agent.
Tenapanor Chemical Structure
BCP24892 Tenapanor 1234423-95-0
Tenapanor is an inhibitor of the Na+/H+ exchanger NHE3 with IC50 values of 5 and 10 nM against human and Rat NHE3, respectively.
Tenapanor dihydrochloride Chemical Structure
BCP24893 Tenapanor dihydrochloride 1234365-97-9
Tenapanor, also known as AZD-1722 and RDX 5791, is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney.
Mexiletine hydrochloride Chemical Structure
BCP28602 Mexiletine hydrochloride 5370-01-4
Mexiletine hydrochloride is a non-selective voltage-gated sodium channel blocker; Class IB anti-arrhythmic compound.
Ralfinamide mesylate Chemical Structure
BCP21638 Ralfinamide mesylate 202825-45-4
Ralfinamide mesylate is a Na+ channel blocker.
ETH 2120 Chemical Structure
BCP28991 ETH 2120 81686-22-8
Sodium ionophore III (ETH2120) is a Na+ ionophore suitable for the assay of sodium activity in blood, plasma, serum. etc.
GNE-131 Chemical Structure
BCP29497 GNE-131 1629063-81-5
GNE-131 is a Potent and Selective hNaV1.7 Inhibitor (Na V1.7 IC50 = 3 nM) for the Treatment of Pain.
Benzamil Chemical Structure
BCP29493 Benzamil 2898-76-2
Benzamil or benzyl amiloride is a potent blocker of the ENaC channel and also a sodium-calcium exchange blocker.
XEN 907 Chemical Structure
BCP23954 XEN 907 912656-34-9
XEN907 is a novel spirooxindole NaV1.7 blocker, inhibits hNaV1.7 with IC50 of 3 nM.
Rufinamide Chemical Structure
BCP21828 Rufinamide 106308-44-5
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
123下一页末页共 56 条记录 1 / 6 页